Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: Effects of gemfibrozil

Pharmaceutical Research

Volumn 22, Issue 7, 2005, Pages 1101-1109

  Prueksaritanont, Thomayant ^a   Qiu, Yue ^a   Mu, Lillian ^a   Michel, Kimberly ^a   Brunner, Janice ^a   Richards, Karen M ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gemfibrozil; Hepatocytes; Interconversion; Metabolism; Pharmacokinetics; Simvastatin; Simvastatin acid; Statins

Indexed keywords

SIMVASTATIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; LIVER CELL; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CELLS, CULTURED; DOGS; GEMFIBROZIL; HEPATOCYTES; HUMANS; HYDROLYSIS; INFUSIONS, INTRAVENOUS; LIVER; SIMVASTATIN;

EID: 23744480403     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-6037-2     Document Type: Article

References (35)

1. V. F. Mauro 1993 Clinical pharmacokinetics and practical applications of simvastatin Clin. Pharmacokinet. 24 195 202
2. D. E. Duggan S. Vickers 1990 Physiological disposition of HMG-CoA-reductase inhibitors Drug Metab. Rev. 22 333 362
3. S. Vickers C. A. Duncan K. P. Vyas P. H. Kari B. Arison S. R. Prakash H. G. Ramjit S. M. Pitzenberger G. Stokker D. E. Duggan 1990 In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase Drug Metab. Dispos. 18 476 483
4. 14C]-atorvastatin in patients with T-tube drainage Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 3 153
5. M. Boberg R. Angerbauer W.K. Kanhai W. Karl A. Kern M. Radtke W. Steinke 1998 Biotransformation of cerivastatin in mice, rats and dogs in vivo Drug Metab. Dispos. 26 640 652
6. D. W. Everett T. J. Chando G. C. Didonato S. M. Singhvi H. Y. Pan S. H. Weinstein 1999 Biotransformation of pravastatin sodium in humans Drug Metab. Dispos. 19 740 748
7. A. E. Black R. N. Hayes B. D. Roth P. Woo T. F. Woolf 1999 Metabolism and excretion of atorvastatin in rats and dogs Drug Metab. Dispos. 27 916 923
8. P. D. Martin M. J. Warwick A. L. Dane S. J. Hill P. B. Giles P. J. Phillips E. Lenz 2003 Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers Clin. Ther. 25 2822 2835
9. T. Prueksaritanont R. Subramanian X. Fang B. Ma Y. Qiu J. H. Lin P. G. Pearson T. A. Baillie 2001 Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab. Dispos. 30 505 512
10. T. Prueksaritanont L. M. Gorham B. Ma L. Liu X. Yu J. J. Zhao D. E. Slaughter B. H. Arison K. P. Vyas 1997 In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab. Dispos. 25 1191 1199
11. T. Prueksaritanont B. Ma N. Yu 2003 Human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, not CYP2D6 Br. J. Clin. Pharmacol. 56 120 124
12. W. Jacobson B. Kuhn A. Soldner G. Kirchner K.-F. Sewing P. A. Kollman L. Z. Benet U. Christians 2001 Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab. Dispos. 28 1369 1378
13. M. Boberg R. Angerbauer P. Fey W. K. Kanhai W. Karl A. Kern J. Ploschke M. Radtke 1997 Metabolism of cerivastatin by human liver microsomes in vitro: characterization of primary metabolic pathways and cytochrome P450 isozymes involved Drug Metab. Dispos. 25 321 331
14. D. J. Rader S. M. Haffner 1999 Roles of fibrates in the management of hypertriglyceridemia Am. J. Cardiol. 83 30F 35F
15. A. Shek M. J. Ferrill 2001 Statin-fibrate combination therapy Ann. Pharmacother. 35 908 917
16. J. T. Backman C. Kyrklund K. T. Kivistö J.-S. Wang P. J. Neuvonen 2000 Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin. Pharmacol. Ther. 68 122 129
17. J. T. Backman C. Kyrklund M. Neuvonen P. J. Neuvonen 2002 Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin. Pharmacol. Ther. 72 685 691
18. C. Kyrklund J. T. Backman K. T. Kivistö M. Neuvonen J. Laitila P. J. Neuvonen 2001 Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin. Pharmacol. Ther. 69 340 345
19. C. Kyrklund J. T. Backman M. Neuvonen P. J. Neuvonen 2003 Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin. Pharmacol. Ther. 73 538 544
20. T. Prueksaritanont J. Zhao B. Ma B. A. Roadcap C. Tang Y. Qiu L. Liu J. H. Lin P. G. Pearson T. A. Baillie 2002 Mechanistic studies on the metabolic interactions between gemfibrozil and statins J. Pharmacol. Exp. Ther. 301 1042 1051
21. J. J. DiStefano 1976 Concepts, properties, measurement, and computation of clearance rates of hormones and other substances in biological systems Ann. Biomed. Eng. 4 302 319
22. J. G. Wagner A. R. DiSanto W. R. Gillespie K. S. Albert 1981 Reversible metabolism and pharmacokinetics: Application to prednisone and prednisolone Res. Commun. Chem. Pathol. Pharmacol. 32 387 405
23. W. F. Ebling W. J. Jusko 1986 The determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits J. Pharmacokin. Biopharm. 14 557 599
24. T. Prueksaritanont C. Tang Y. Qiu L. Mu R. Subramanain J. H. Lin 2002 Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab. Dispos. 30 1280 1287
25. H. Schulz 1987 Inhibitors of fatty acid oxidation Life Sci. 40 1443 1449
26. T. Prueksaritanont, K. M. Richards, Y. Qiu, K. Strong-Basalyga, A. Miller, C. Li, R. Eisenhandler, and E. J. Carlini. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm. Res. 22:71-78 (2005).
27. C. Hamberger J. Barre R. Zini A. Taiclet G. Houin J. P. Tillement 1986 In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs Int. Clin. Pharm. Res. 6 441 449
28. M. G. Soars B. Burchell R. J. Riley 2002 In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance J. Pharmacol. Exp. Ther. 301 382 390
29. R. A. Okerholm F. J. Keeley F. E. Peterson A. J. Glazko 1976 The metabolism of gemfibrozil Proc. R. Soc. Med. 69 Suppl. 2 11 14
30. S. Yoshihisa M. Hirano H. Satao Y. Sugiyama 2004 Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J. Pharmacol. Exp. Ther. 311 228 236
31. J. L. Lam L. Z. Benet 2004 Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes Drug Metab. Dispos. 32 1311 1316
32. B. Hsiang Y. Zhu Z. Wang Y. Wu V. Sasseville W.-P. Yang T. G. Kirchgessner 1999 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J. Biol. Chem. 274 37161 37168
33. J. H. Hochman N. T. Pudvah Y. Qiu M. Yamazaki C. Tang J. H. Lin T. Prueksaritanont 2004 Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin Pharm. Res. 21 1688 1693
34. M. Yamazaki, B. Li, S. W. Louie, N. T. Pudvah, R. Stocco, W. Wong, M. Abramovitz, A. Demartis, R. Laufer, J. H. Hochman, T. Prueksaritanont, and J. H. Lin. Effects of fibrates on human organic anion-transporting polypeptide 1B1 (OATP2, OATP-C, SLC21A6)-, multidrug resistance protein 2 (MRP2/ABCC2)-, and P-glycoprotein (ABCB1)-mediated transport. Xenobiotica in press.
35. A. J. Bergman G. Murphy J. Burke J. J. Zhao R. Valesky L. Liu K. C. Lasseter W. He T. Prueksaritanont Y. Qiu A. Hartford J. M. Vega J. F. Paolini 2004 Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans J. Clin. Pharmacol. 44 1054 1062